- Home
- RNXT vs FBLG Comparison
RNXT vs FBLG Comparison
Compare RNXT & FBLG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RNXT
- FBLG
- Stock Information
- Founded
- RNXT 2012
- FBLG 2021
- Country
- RNXT United States
- FBLG United States
- Employees
- RNXT N/A
- FBLG N/A
- Industry
- RNXT Biotechnology: Pharmaceutical Preparations
- FBLG
- Sector
- RNXT Health Care
- FBLG
- Exchange
- RNXT Nasdaq
- FBLG NYSE
- Market Cap
- RNXT 44.6M
- FBLG 37.1M
- IPO Year
- RNXT 2021
- FBLG 2024
- Fundamental
- Price
- RNXT $1.32
- FBLG $0.70
- Analyst Decision
- RNXT Strong Buy
- FBLG Strong Buy
- Analyst Count
- RNXT 2
- FBLG 4
- Target Price
- RNXT $7.25
- FBLG $13.00
- AVG Volume (30 Days)
- RNXT 150.2K
- FBLG 559.7K
- Earning Date
- RNXT 08-14-2025
- FBLG 08-06-2025
- Dividend Yield
- RNXT N/A
- FBLG N/A
- EPS Growth
- RNXT N/A
- FBLG N/A
- EPS
- RNXT N/A
- FBLG N/A
- Revenue
- RNXT $240,000.00
- FBLG N/A
- Revenue This Year
- RNXT $3,104.65
- FBLG N/A
- Revenue Next Year
- RNXT $301.89
- FBLG N/A
- P/E Ratio
- RNXT N/A
- FBLG N/A
- Revenue Growth
- RNXT N/A
- FBLG N/A
- 52 Week Low
- RNXT $0.75
- FBLG $0.58
- 52 Week High
- RNXT $1.69
- FBLG $5.62
- Technical
- Relative Strength Index (RSI)
- RNXT 50.28
- FBLG 45.24
- Support Level
- RNXT $1.28
- FBLG $0.61
- Resistance Level
- RNXT $1.40
- FBLG $0.68
- Average True Range (ATR)
- RNXT 0.07
- FBLG 0.05
- MACD
- RNXT -0.01
- FBLG 0.01
- Stochastic Oscillator
- RNXT 40.74
- FBLG 54.91
About RNXT RenovoRx Inc.
RenovoRx Inc is a clinical-stage biopharmaceutical company developing proprietary targeted combination therapies for high unmet medical need with a goal to improve therapeutic outcomes for cancer patients undergoing treatment. RenovoRx's patented Trans-Arterial Micro-Perfusion therapy platform is designed to ensure precise therapeutic delivery to directly target the tumor while potentially minimizing a therapy's toxicities versus systemic intravenous therapy.
About FBLG FIBROBIOLOGICS INC
FibroBiologics Inc is a clinical-stage cell therapy company focused on developing and commercializing fibroblast-based therapies for patients suffering from chronic diseases with significant unmet medical needs, including degenerative disc disease, multiple sclerosis, wound healing, and certain cancers, and potential extension of life applications including thymic and splenic involution reversal.